FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×